Grünenthal Limited
TOR Building
St Cloud Way
Maidenhead SL6 8BN
Phone: +44 (0)870 351 8960

For Medical Information, Reporting Safety and Quality Related Issues see here

... About us

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 29 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 100 countries and we employ around 4,700 employees worldwide.

... Company Overview

Although firmly rooted in Germany, today we are very much a growing global business.

... History

At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact on society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.

... Responsibility

Although firmly rooted in Germany, today we’re very much a growing global business, represented in 27 countries and maintaining production sites in five.

... Global Capabilities

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives

... Requests for Funding

Patients’ needs are at the heart of everything we do; using our passion for science, we develop long-lasting solutions that directly address these needs.

... Products

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Ationdo.

... Ationdo

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Nebido.

... Nebido

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Palexia.

... Palexia

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Qutenza.

... Qutenza

We are dedicated to creating a better future for our patients, Read the package leaflet information to find out more about Ralvo.

... Ralvo

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Tramacet.

... Tramacet

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Versatis.

... Versatis

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Vimovo .

... Vimovo

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Zydol.

... Zydol

We are dedicated to creating a better future for our patients, read the package leaflet information to find out more about Zomig.

... Zomig

Patients’ needs are at the heart of everything we do; using our passion for science, we develop long-lasting solutions that directly address these needs. Read the package leaflet information to find out more about our products.

... Reporting Safety and Quality Related complaints

Where we come from - The Grünenthal history

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. As an integrated research and development company, we have a strong track record of bringing pain treatments to patients.

Grünenthal Ltd., UK, a subsidiary of Grünenthal GmbH, was established in 2004.
With headquarters in TOR Buildings, Saint-Cloud Way, Maidenhead SL6 8BN, the company includes Regulatory, Medical Information, Sales and Marketing divisions as well as Market Access and Medical Science Liaison teams.

Grünenthal Ltd, UK, Stokenchurch

2004 Foundation

Grünenthal UK made their first sales.

Zydol®

2006 Company launched to promote Zydol® and Zydol® SR (tramadol hydrochloride)

Versatis® lidocaine 700mg medicated plaster

2007 Launch of Versatis® (lidocaine 700mg medicated plaster)

Palexia®

2011 Launch of Palexia® (tapentadol tablets) and Palexia SR® (tapentadol prolonged release)

Recivit®

2014 Recivit® (fentanyl) & Palexia® (tapentadol oral solution) Launch

Please note Recivit® is no longer marketed by Grunenthal UK.

Qutenza

2017 Acquisition of Qutenza™ (capsaicin 179mg cutaneous patch)

2022 Nebido^® (Testosterone undecanoate)

M-ALL-UK-01-24-0004 - January 2024